MaxCyte IPO Presentation Deck
Growing Opportunity from R&D to Therapeutics
DRUG DISCOVERY & DEVELOPMENT
- CELLS TO DISCOVER DRUGS
Blue-chip client base includes the top ten global pharma
companies and 20 of the top 25*
MaxCyte Revenue Model
Instrument sale**
Single-use disposables
(processing assemblies)
Razor/razor blade economics
Top pharma by revenue
Includes RUO-non-exclusive license only: $119,000 list price for STX sale
July 2021
STX ATX
J
13 SPLs with cell therapy developers that allow for more than 75
clinical programs; > $950m in potential pre-commercial milestones
CELL THERAPY - CELLS AS DRUGS
CONFIDENTIAL
GT%
MaxCyte Revenue Model
Annual instrument license fee***
Single-use disposables
(processing assemblies)
Strategic partnership terms
Razor/razor blade economics and share of
therapeutic economics
*** $150,000 per year lease price for pre-clinical use or $250,000 per year lease price for clinical use
12View entire presentation